Sep 2026· European Urology· 0 citations· 7 references
Medicine
Abstract
Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing the risk of overinterpreting nontumour or nonactionable genomic alterations.
In this feasibility study, plasma cfRNA transcriptomes from 64 men with prostate cancer on active surveillance revealed differences between stable disease and progression to radical prostatectomy and suggested a predominantly non-tumour origin of circulating RNA. These findings demonstrate the feasibility of cfRNA tran...
J. G. Foster, Eva Wozniak, C. Mein et al.· bioRxiv· 0 citations
The conceptual landscape of clinical oncology and cancer biology has undergone a profound transformation in recent decades, evolving from static anatomical staging and broad histopathological classification into a dynamic, molecularly stratified discipline [...].
Chia-Ching Chen, Hsin-Hung Chen, Po-Ming Chen· Current Issues in Molecular...· 0 citations
Findings support next-generation sequencing-based ctDNA as a prognostic biomarker to refine risk stratification in patients undergoing neoadjuvant therapy.
Krishay Sridalla, Dominic J. Vitello, Madison Cox et al.· Annals of Surgical Oncology· 0 citations
Summary MTAP loss is among the most common potentially targetable driver mutations in NSCLC. Early phase clinical trials are ongoing. Although susceptible to various biases, retrospective studies may serve as a historical control to interpret single arm studies. Combination therapies and novel biomarkers may also impro...
Daniel Li, E. Garon· Clinical Cancer Research· 0 citations
Highlights • HALP integrates anemia, nutrition, immunity, and systemic inflammation.• Low HALP is generally linked to poorer outcomes across solid tumors.• Cutoff heterogeneity limits threshold transferability and clinical use.• Prospective validation is required before routine implementation.
Zian Jin, Chang-Hong Dong, K. Hui et al.· Translational Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
